Welcome to our dedicated page for Enova International SEC filings (Ticker: ENVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Enova International's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Enova International's regulatory disclosures and financial reporting.
Enova International, Inc. (NYSE: ENVA) – Form 144 notice
Insider James Lee intends to sell up to 478 common shares through Morgan Stanley Smith Barney, with an estimated aggregate value of $50,484. The planned trade may occur on or after 29 Jul 2025 on the NYSE. Relative to the 25.0 million shares outstanding, the sale equals roughly 0.002 %, indicating a de-minimis transaction. The shares originate from restricted-stock grants received on 9 and 11 Feb 2024 (359 and 119 shares). Lee previously sold 550 shares on 2 May 2025 for $52,109.
The filing is procedural under Rule 144 and does not disclose any operational or financial developments. Given the very small size, it is unlikely to influence ENVA’s capital structure, liquidity, or share-price dynamics.
Form 4 highlights for Enova International, Inc. (ENVA): On 06/20/2025, Chief Executive Officer and Director David Fisher exercised 2,000 non-qualified stock options at an exercise price of $23.96 (code “M”) and immediately sold the same 2,000 common shares in the open market at a weighted-average price of $98.4214 (code “S”).
• Gross spread captured: approximately $74.46 per share, or roughly $149,000 in pre-tax proceeds.
• Remaining direct ownership: 348,223 common shares after the transactions, down from 350,223.
• Outstanding options: 170,562 options remain unexercised on the same grant, expiring 02/12/2026. The option set vested in three equal tranches between 2020 and 2022.
The sale was executed under Fisher’s established Rule 10b5-1 trading plan, limiting the informational signal for investors. The option/SAR pair was granted with a limited stock-appreciation right that becomes exercisable only upon a Change in Control scenario; exercising the option automatically terminates the corresponding SAR.
Materiality assessment: The transaction represents less than 1% of Fisher’s total common-stock holdings and does not involve new share issuance or company-level cash flows. Therefore, the filing is viewed as routine insider portfolio management, with negligible direct effect on Enova’s capital structure or near-term financial outlook.
Enova International, Inc. (ENVA) has filed a Form 144 notifying the SEC of a proposed sale of 2,000 common shares through Merrill Lynch on the NYSE, tentatively scheduled for 06/20/2025. The aggregate market value is listed at $196,760, implying an estimated price of about $98.38 per share. With 25,366,770 shares outstanding, the transaction represents less than 0.01 % of total shares.
The filing names David Fisher as the seller. Over the past three months he has already disposed of 9,000 shares (5,000 on 03/25/2025, 2,000 on 04/28/2025 and 2,000 on 05/22/2025) for cumulative gross proceeds of $888,721.90. If the newly noticed sale is executed, total dispositions would rise to 11,000 shares. The shares being sold were originally acquired via stock-option exercises in February 2019.
Form 144 filings merely signal an intent and do not obligate the insider to complete the sale. The document contains no additional financial metrics or strategic commentary.